



**Apixaban  
Accord**  
accord

10 7208 0 6028463

accord

## PATIENT ALERT CARD

**Apixaban Accord (apixaban)  
Patient Alert Card**

**Carry this card with you at all times**

**Show this card to your pharmacist,  
dentist and any other healthcare  
professionals that treat you.**

**I am under anticoagulation treatment  
with Apixaban Accord (apixaban) to  
prevent blood clots**

**Please complete this section or ask  
your doctor to do it**

Name:

Birth Date:

Indication:

Dose:     mg twice daily

Doctor's Name:

Doctor's telephone:

### **Information for patients**

- Take Apixaban Accord regularly as instructed. If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule.
- Do not stop taking Apixaban Accord without talking to your doctor, as you are at risk of suffering from a stroke or other complications.
- Apixaban Accord helps to thin your blood. However, this may increase your risk of bleeding.
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.
- If the bleeding does not stop on its own, **seek medical attention immediately.**
- If you need surgery or any invasive procedure, inform your doctor that you are taking Apixaban Accord.

### **Information for healthcare professionals**

- Apixaban Accord (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- Apixaban Accord may increase the risk of bleeding. In case of major bleeding

events, it should be stopped immediately.

- Treatment with Apixaban Accord does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalised ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.
- An agent to reverse the anti-factor Xa activity of apixaban is available.

Version 1. Date of HPRA approval:  
February 2024